Abstract | BACKGROUND: METHODS: RESULTS: Despite similarly elevated receptor expression in UC and CRC, IL-13 does not activate the STAT6 or MAPK pathways in UC, while in colonic tumors only the STAT6 pathway is activated. Using neutralizing antibodies and cell lines expressing a range of surface densities for IL-13Ralpha1 and IL-3Ralpha2, we demonstrate that IL-13Ralpha2 serves a dual role, initiating MAPK signaling at low concentrations and as an inhibitory, decoy receptor at high IL-13Ralpha2 to IL-13Ralpha1 ratios. CONCLUSIONS: IL-13Ralpha2 is both a decoy receptor and induces MAPK signal transduction, depending on its relative expression and the local concentration of IL-13, which together modulate the balance and intensity of the signaling pathways initiated in UC and CRC.
|
Authors | Debasmita Mandal, Alan D Levine |
Journal | Inflammatory bowel diseases
(Inflamm Bowel Dis)
Vol. 16
Issue 5
Pg. 753-64
(May 2010)
ISSN: 1536-4844 [Electronic] England |
PMID | 20014020
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Retracted Publication)
|
Chemical References |
- Antibodies, Neutralizing
- Cytokines
- Interleukin-13
- Interleukin-13 Receptor alpha1 Subunit
- Interleukin-13 Receptor alpha2 Subunit
- STAT3 Transcription Factor
- STAT3 protein, human
- Mitogen-Activated Protein Kinases
|
Topics |
- Antibodies, Neutralizing
(pharmacology)
- Blotting, Western
- Cells, Cultured
- Colitis, Ulcerative
(metabolism)
- Colon
(cytology, metabolism)
- Colorectal Neoplasms
(metabolism)
- Cytokines
(metabolism)
- Flow Cytometry
- Humans
- Interleukin-13
(metabolism)
- Interleukin-13 Receptor alpha1 Subunit
(metabolism)
- Interleukin-13 Receptor alpha2 Subunit
(metabolism)
- Intestinal Mucosa
(cytology, metabolism)
- Mitogen-Activated Protein Kinases
(metabolism)
- STAT3 Transcription Factor
(metabolism)
- Signal Transduction
|